Arcus Biosciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-369	-353	-283	-307	-267	53
Depreciation & Amortization	9	10	10	8	6	4
Stock-Based Compensation	63	60	76	73	65	55
Other Adjustments	-5	-5	5	-9	11	13
Changes in Accounts Payable	-	24	3	-1	8	-5
Changes in Unearned Revenue	-229	-240	-56	-68	-112	-368
Changes in Other Operating Activities	23	22	75	-2	727	-3
Operating Cash Flow	-488	-482	-170	-306	438	-256
Operating Cash Flow Growth	-	-	-	-	-	-
Capital Expenditures	-1	-2	-6	-24	-6	-26
Purchases of Investments	-873	-1,076	-1,043	-788	-1,241	-719
Proceeds from Sale of Investments	1,022	1,144	965	1,006	837	741
Other Investing Activities	-	-	-	-	-3	-
Investing Cash Flow	148	66	-84	194	-413	-4
Long-Term Debt Issued	-	49	47	-	-	-
Net Long-Term Debt Issued (Repaid)	-	49	47	-	-	-
Issuance of Common Stock	300	439	237	33	23	232
Repurchase of Common Stock	-	-	-7	-	-	-
Net Common Stock Issued (Repurchased)	300	439	230	33	23	232
Other Financing Activities	-	-	-	-	10	5
Financing Cash Flow	349	488	277	33	33	237
Net Cash Flow	9	72	23	-79	58	-23
Free Cash Flow	-489	-484	-176	-330	432	-282
Free Cash Flow Growth	-	-	-	-	-	-
FCF Margin	-207.20%	-195.95%	-68.22%	-282.05%	385.71%	-73.63%
Free Cash Flow Per Share	-4.28	-4.51	-1.95	-4.46	6.00	-3.81
Levered Free Cash Flow	-567	-490	-210	-394	356	-345
Unlevered Free Cash Flow	-596	-572	-305.17	-433.78	341.95	-345.96

SEC Filings: 10-K · 10-Q